My Blog
From ‘Skinny Jab’ to Health Equity: How Media Shapes the Obesity Treatment Debate
Over the past year, the public conversation around obesity treatment has intensified. GLP-1 receptor agonists, such as semaglutide and tirzepatide, have transformed the therapeutic landscape. But while clinical science has advanced, media narratives have not kept...
From ‘Skinny Jab’ to Health Equity: How Media Shapes the Obesity Treatment Debate
Over the past year, the public conversation around obesity treatment has...
What’s the Difference Between “No Known Health Benefits” and “Detrimental to Your Health”?
Why Food Labelling Language Matters in the Age of Chronic Disease and Therapeutic Nutrition In today’s food...
When the Slowest Stakeholder Sets the Pace: What Sickle Cell and Thalassemia Reveal About Europe’s Rare Disease Reform
As trilogue negotiations begin on the EU’s pharmaceutical package, there’s a renewed focus on access, innovation, and...
GLP-1s and the Weight Loss Illusion: What Investors and Regulators Are Missing
GLP-1 drugs are transforming obesity treatment, but focusing solely on weight loss may be misleading. This article explores how metabolic biomarkers like inflammation and insulin sensitivity could offer a more accurate measure of success, reshaping regulatory thinking and investor strategy.
Why AI Writing Tools Are a Game-Changer for Adults with Autism and ADHD. And What EU Employers Need to Know
Let’s start with something I hear far too often:“Isn’t using AI to help with writing… cheating?” Let me be absolutely...
From Exercise to Movement: Why the WHO’s Language Shift Matters for Health Tech: and What Investors Should Be Watching
There’s been a quiet but meaningful shift in how the World Health Organization talks about physical activity. If...
Seeing the System: The Power and Price of Pattern Recognition in Health Policy
If there’s one skill that’s shaped my career in health system transformation and policy stakeholder engagement, it’s...